E Point Perfect
Law \ Legal

Antitrust + Competition Life Sciences Quarterly Update Q2 2022


Although the second quarter did not feature any life sciences enforcement action by the FTC, there was plenty of news in and around the space. The FTC held a detailed “virtual workshop” as part of its pharmaceutical merger task force and news emerged of a potential Merck-Seagen deal that could set up an interesting test of the FTC’s new enforcement priorities. Finally, the FTC’s recent complaint seeking to stop the proposed Meta/Within transaction offers potential insight into how the new Democratic majority might approach a large pharmaceutical transaction. Antitrust + Competition lawyers Arman OrucAndrew LacySarah Jordan and Elliot Silver discuss these developments in the Antitrust + Competition Life Sciences Quarterly Update.

The post Antitrust + Competition Life Sciences Quarterly Update Q2 2022 appeared first on Life Sciences Perspectives.



Source link

Related posts

Controller A (EEA) → Processor Z (EEA) → Controller B (Non-EEA)

Dawn Zuniga

Food Labeling Claims Get the Boot in Texas

Dawn Zuniga

EDTX Denies Discovery of Litigation Funding Documents

Dawn Zuniga

Another trial lawyer was named in the Blue Bell case for Aug. 1 jury trial

Dawn Zuniga

Dill recalled in Ontario because of Listeria contamination

Dawn Zuniga

Does the USMCA Mean What It Says? The Disputes Panel Hearing on the Auto Core Parts Rules of Origin

Dawn Zuniga